Pyoderma gangrenosum, acne conglobata, suppurative hidradenitis, and axial spondyloarthritis: efficacy of anti-tumor necrosis factor α therapy.

Abstract

We report the case of a patient with a simultaneous presence of pyoderma gangrenosum, acne conglobata, suppurative hidradenitis, and axial spondyloarthritis. This condition differs from both the PASH (pyoderma gangrenosum, acne, and suppurative hidradenitis) syndrome, in which arthritis is absent, and the PAPA (pyogenic arthritis, pyoderma gangrenosum, and acne) syndrome, in which suppurative hidradenitis is lacking. Our patient failed to respond to etanercept therapy, whereas all dermatologic and rheumatic manifestations completely regressed following infliximab infusion. We therefore propose that simultaneous presence of pyoderma gangrenosum, acne conglobata, suppurative hidradenitis, and seronegative spondyloarthritis might represent a distinct syndrome that could be termed the PASS syndrome. Tumor necrosis factor α therapies seem to play selective roles.

• Authors: Vincenzo Bruzzese
• Journal: Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases (J Clin Rheumatol) Vol. 18 Issue 8 Pg. 413-5 (Dec 2012) ISSN: 1536-7355 [Electronic] United States
• PMID: 23188209 (Publication Type: Case Reports, Journal Article)

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Antibodies, Monoclonal
• Tumor Necrosis Factor-alpha
• C-Reactive Protein
• Infliximab
• Isoniazid

Topics

• Acne Vulgaris (complications, drug therapy)
• Adult
• Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)
• Antibodies, Monoclonal (therapeutic use)
• Blood Sedimentation
• C-Reactive Protein (analysis)
• Hidradenitis Suppurativa (complications, drug therapy)
• Humans
• Infliximab
• Infusions, Intravenous
• Isoniazid (therapeutic use)
• Male
• Pyoderma Gangrenosum (complications, drug therapy)
• Spondylarthritis (complications, drug therapy)
• Tumor Necrosis Factor-alpha (antagonists & inhibitors)